Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...

Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trialImprovement 1.9 to 2.4 times greater with highest dose than with placeboTrial to proceed with Part B to test AM-125...